Use of agents stimulating erythropoiesis in digestive diseases.
Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron deficiency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as first choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same efficacy and safety.
Moreno López
Rosario
R
Department of Nephrology, San Juan de Dios Hospital, Paseo Colón, 14, 50006 Zaragoza, Spain. charomorenol@gmail.com
Sicilia Aladrén
Beatriz
B
Gomollón García
Fernando
F
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006397:Hematinics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D012254:Ribavirin / Q000009:adverse effects
D006397:Hematinics; D004921:Erythropoietin; D012254:Ribavirin